Clinical Trials · NCT06642584
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 90
- Start date
- Oct 2024
- Locations
- 1 site, Canada
- Primary endpoint
- Adjusted AUC(sema); adjusted area under the semaglutide plasma concentration-time curve